Author of

• 20171

  +

  P2.07 - Immunology and Immunotherapy (ID 708)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23378

    +

    P2.07-003 - Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer (ID 7914)

    09:30 - 09:30  |  Author(s): Y.H. Kim
    • Abstract

    Background:
    Programmed death-1 (PD-1) inhibitor, nivolumab, is one of the standard second-line treatments for advanced non-small cell lung cancer (NSCLC); however, its efficacy for patients with epidermal growth factor receptor (EGFR) mutation is still debatable.
    
    Method:
    We retrospectively reviewed the medical records of 82 patients with advanced NSCLC who were treated with nivolumab at Kyoto University Hospital between December 2015 and December 2016, and identified 24 patients harboring EGFR mutation. In this analysis, 1) treatment effect was compared between patients with and without EGFR mutation, and 2) clinical characteristics affecting the efficacy of nivolumab were examined in patients with EGFR mutation.
    
    Result:
    Overall response rate (ORR) was 13% and disease control rate (DCR) was 44% in the entire population. ORR (8% versus 15%, p=0.37) and DCR (25% versus 51%, p=0.024) were lower in patients with EGFR mutation compared with those in patients without EGFR mutation. Median progression-free survival (PFS) was 2.0 months for the entire population (95% confidence interval [CI], 1.73-2.57), and 1.8 and 2.2 months for EGFR mutation-positive and EGFR mutation-negative patients, respectively (hazard ratio [HR]=0.68 (95% CI, 0.4-1.19), p=0.17). In the EGFR mutation-positive population, higher Brinkman index and shorter response duration with precedent EGFR-TKI were correlated with longer PFS with nivolumab. Three patients with EGFR mutation achieved durable disease control lasting more than 1 year, two of whom harbored uncommon EGFR mutation (G719X).
    
    Conclusion:
    Nivolumab had limited efficacy in EGFR mutation-positive NSCLC patients; however, some patients derived meaningful clinical benefit from nivolumab. Further studies are warranted to elucidate the clinical characteristics predicting the efficacy of nivolumab in this population.